Bristol Says New Version of Opdivo on Track to Meet Target (1)

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at least 30% of patients in two years.

“We’re really seeing nice uptake and conversion,” Chief Commercialization Officer Adam Lenkowsky said in an interview on the sidelines of the JPMorgan Healthcare conference. “We’re seeing that across a multitude of tumor types.”

US regulators approved the new version of the drug, called Opdivo Qvantig, in late 2024. Bristol has said the injectable version treats patients faster and ...